Diligence memo · auto-generated · as of July 1, 2026
Ndea
Ndea: limited disclosed financing to assess.
Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.
Businessfiled
Ndea operates in Pharma, based in Remote. Building AGI that can innovate.
Sub-sector tags: Artificial Intelligence, Deep Learning, Hard Tech, ML, Remote Work, ai/ml, pharma, robotics.
Capital & rounds (filed)filed
Ndea has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.
Valuation (modeled)modeled
No modeled valuation — too little disclosed financing to estimate one.
Financing rhythm & timingmixed
Not enough dated financing history to read a financing rhythm.
Comparablesmixed
Capital scale ranks ahead of 16% of Pharma peers (310 compared).
Modeled value ranks above 16% of those peers.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.